BILAYER THERAPEUTICS
Bilayer Therapeutics is a biotech company that develops a first-in-class therapeutic for constipation and other diseases of the colon. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.
BILAYER THERAPEUTICS
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2020-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.bilayer-therapeutics.com
Status:
Active
Contact:
734-358-9015
Email Addresses:
[email protected]
Total Funding:
2 M USD
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Oceana Therapeutics
Oceana Therapeutics is a global company committed to commercializing best-in-class therapeutics with a focus on colorectal,
Thrombolytic Science International
Thrombolytic Science International develops a clot-dissolving therapy for stroke and other thrombotic diseases.
Via Nova Therapeutics
Via Nova Therapeutics is to discover and develop therapeutics for acute and subacute viral infections.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Voyager Therapeutics
Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system
Current Employees Featured
Official Site Inspections
http://www.bilayer-therapeutics.com
- Host name: 241.114.215.35.bc.googleusercontent.com
- IP address: 35.215.114.241
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Bilayer Therapeutics" on Search Engine
Bilayer Therapeutics Company Profile 2024: Valuation, …
Bilayer Therapeutics Overview. Update this profile. Year Founded. 2020. Status. Private. Employees. 3. Latest Deal Type. Series A. (In Progress) Latest Deal Amount. $14M. …See details»
Bilayer Therapeutics | LinkedIn
About us. Bilayer Therapeutics is a development-stage company founded by a team of world-renowned drug development and delivery experts and gastroenterologists. Its …See details»
Bilayer Therapeutics, Inc. | BioPharm America - Informa Connect
Profile. Company/Organization Description. Bilayer Therapeutic, Inc. was formed to develop BL-010, a bile acid-based, first-in-class therapeutic for constipation and to …See details»
Bilayer Therapeutics, Inc. - BIO International Convention 2024
Bilayer Therapeutics seeks to develop bile acids as first-in-class therapies to treat several diseases of the colon using an incretin-based mechanism of action and a unique and …See details»
Bilayer Therapeutics, Inc. | CipherBio
Bilayer Therapeutics is a biotech company that develops a first-in-class therapeutic for constipation and other diseases of the colon. The company was founded in 2020 and is …See details»
Thomas A. Collet, PhD - Bilayer Therapeutics
Thomas A. Collet, PhD - Bilayer Therapeutics. Position: President, CEO & Director. Thomas Collet is a serial life sciences entrepreneur with deep drug development …See details»
Bilayer Therapeutics - Contacts, Employees, Board …
Bilayer Therapeutics is a biotech company that develops a first-in-class therapeutic for constipation and other diseases of the colon.See details»
Bilayered delivery system offers new solution for treating …
Dec 9, 2020 Researchers at Brigham and Women's Hospital and the Massachusetts Institute of Technology (MIT) devised a plan to deliver CDC in a bilayered capsule, …See details»
Joshua Korzenik, MD - Bilayer Therapeutics
Position: Director & Medical Advisor, Brigham and Women’s Hospital. Dr. Joshua R. Korzenik, one of the leading IBD researchers and key opinion leaders in the country, is …See details»
Bilayer Therapeutics, Inc. | VentureRadar
Founded in 2020. Private Company. Develops innovative treatments for constipation and diarrhea using naturally occurring bile acid and proprietary bilayer tablet technology, …See details»
New treatment in development for irritable bo | EurekAlert!
News Release 8-Dec-2020. New treatment in development for irritable bowel syndrome with constipation. Preclinical study finds that an innovative bilayered capsule can overcome …See details»
Bilayer tablets: A developing novel drug delivery system
Dec 1, 2020 Bilayer tablet. Today, several countries, including the developing and the developed ones, have started to consider using combination therapy for treating several …See details»
Bilayer Therapeutics, Inc. - BIO International Convention | BIO
Jun 6, 2023 Bilayer Therapeutics, Inc. The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and …See details»
Screening for bilayer-active and likely cytotoxic molecules reveals ...
Apr 4, 2023 Conformational changes (from, say, state I to state II) that involve the proteins’ bilayer-spanning domains (Fig. 1), therefore, will alter the organization of the adjacent …See details»
Bilayer Therapeutics - Crunchbase
Bilayer Therapeutics is a biotech company that develops a first-in-class therapeutic for constipation and other diseases of the colon.See details»
Bilayer Therapeutics - Updates, News, Events, Signals & Triggers
Start Your Free Trial. Bilayer Therapeutics is a biotech company that develops a first-in-class therapeutic for constipation and other diseases of the colon.See details»
Bilayer Therapeutics - Raised $2.3M Funding from 2 investors
Mar 22, 2024 $2.3M. $2M in Largest Round. Investors. 2 Institutional. Bilayer Therapeutics Funding. How much funding did Bilayer Therapeutics raise in its latest …See details»
BL-010 (Bilayer Therapeutics) - Drug Targets, Indications, Patents ...
May 1, 2024 BL-010 (Bilayer Therapeutics), Initially developed by Bilayer Therapeutics, Inc., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Nervous …See details»
President & CEO @ Bilayer Therapeutics - Crunchbase
Thomas A. Collet. Summary. Overview. Number of Founded Organizations 2. CB Rank (Person) 299,555. Primary Job Title President & CEO. Primary Organization. Bilayer …See details»
BL-040 - Drug Targets, Indications, Patents - Synapse
Apr 1, 2024 Overview. Basic Info. Drug Type. Small molecule drug. Synonyms. Target - Mechanism - Therapeutic Areas. Digestive System Disorders. Active Indication. Crohn …See details»